Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fluxion Biosciences Introduces IsoFlux™ NGS Assay Kits

Published: Tuesday, April 22, 2014
Last Updated: Monday, April 21, 2014
Bookmark and Share
New kits enable mutation detection from circulating tumor cells using next-generation sequencing.

Fluxion Biosciences has announced the introduction of a new series of assay kits design to enhance and complete the workflow for next-generation sequencing (NGS) using the IsoFlux System.

The IsoFlux™ NGS assay kits are designed to work with circulating tumor material enriched on the IsoFlux System. They significantly increase the overall target purity of the sample and provide a robust nucleic acid extraction method that is optimized for next-generation sequencing.

The IsoFlux NGS assay kits are available for immediate use through the IsoFlux Discovery Services program, with kit shipments to IsoFlux customers starting in June 2014.

Circulating tumor cells (CTCs) enable access to tumor material without the need for a surgical biopsy. CTCs possess the key advantage of being able to be enriched over the background blood cells, making it possible to analyze them using molecular methods.

Other approaches to obtaining tumor material from the circulation, such as cell-free DNA, have limitations in this regard. Despite recent advances in CTC technologies, it remains a persistent challenge to enrich sufficiently to meet the rigorous requirements of next-generation sequencing platforms.

The IsoFlux NGS assay kits incorporate a proprietary method of purity enhancement that, when combined with the IsoFlux System for primary enrichment, delivers a high purity DNA or RNA sample immediately ready for next-generation sequencing.

Next-generation sequencing plays an essential role in the emerging field of precision medicine. Clinical scientists have utilized NGS to learn how and why patients may respond or fail to particular therapies. They can employ NGS to learn how to best predict which therapies a patient might respond to over time.

Timely access to tumor material has been the primary limitation to this approach. Serial tissue biopsy is not generally practiced due to the high risks, high costs, and limited success rates.

The IsoFlux NGS kits provide a valuable tool to clinical scientists and drug developers to track the course of disease for an individual patient and as part of broader research studies.

The IsoFlux NGS kits have been developed and validated with leading commercial NGS platforms and cancer mutation panels ranging from 5 to 500 genes of interest to cancer.

“The IsoFlux NGS assay kits deliver on the promise of where precision medicine is heading,” said Jeff Jensen, CEO at Fluxion. “The ability to analyze a broad range of cancer biomarkers in a single blood-based test provides critical information that will help inform the next generation of targeted therapies and diagnostics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fluxion Biosciences, UT Health Collaborate
Company has announced collaboration with UT Health to develop novel liquid biopsy approaches to improve the ability to diagnose, monitor, and treat cancer patients.
Saturday, April 30, 2016
Fluxion Biosciences to Distribute Millipore PrecisION® Ion Channel Cell Lines
Combination with IonFlux™ automated patch clamp system creates a validated, affordable solution for ion channel profiling and screening.
Thursday, December 22, 2011
Ohio State University Researchers Adopt IonFlux 16 Automated Patch Clamp System
First of kind high throughput instrument for research applications enables ion channel studies.
Monday, August 16, 2010
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!